Cargando…

Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3β/Nrf2 Pathway

Folic acid- (FA-) induced kidney injury is characterized by the tubule damage due to the disturbance of the antioxidant system and subsequent interstitial fibrosis. FG-4592 is an inhibitor of prolyl hydroxylase of hypoxia-inducible factor (HIF), an antioxidant factor. The present study investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xue, Zou, Yu, Xing, Jia, Fu, Yuan-Yuan, Wang, Kai-Yue, Wan, Peng-Zhi, Zhai, Xiao-Yue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995323/ https://www.ncbi.nlm.nih.gov/pubmed/32051732 http://dx.doi.org/10.1155/2020/6286984

Ejemplares similares

Roxadustat (FG-4592) Facilitates Recovery From Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid
por: Li, Xue, et al.
Publicado: (2022)

Radioprotective effects of roxadustat (FG‐4592) in haematopoietic system
por: Zhang, Pei, et al.
Publicado: (2018)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways
por: Long, Guangfeng, et al.
Publicado: (2020)

Roxadustat (FG-4592) abated lipopolysaccharides-induced depressive-like symptoms via PI3K signaling
por: Li, Axiang, et al.
Publicado: (2023)

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation
por: Miao, A-Feng, et al.
Publicado: (2021)

Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action
por: Chang, Wei-Ting, et al.
Publicado: (2019)

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
por: Besarab, Anatole, et al.
Publicado: (2015)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model
por: Zhou, Muran, et al.
Publicado: (2019)

Osteoblast–Osteoclast Coculture Amplifies Inhibitory Effects of FG‐4592 on Human Osteoclastogenesis and Reduces Bone Resorption
por: Hulley, Philippa A, et al.
Publicado: (2020)

FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway
por: Feng, Zhenlan, et al.
Publicado: (2022)

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
por: Chen, Nan, et al.
Publicado: (2017)

Moxibustion Protects Dopaminergic Neurons in Parkinson's Disease through Antiferroptosis
por: Huang, Zifeng, et al.
Publicado: (2021)

Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson’s Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function
por: Li, Xuan, et al.
Publicado: (2018)

Moxibustion Exerts a Neuroprotective Effect through Antiferroptosis in Parkinson's Disease
por: Lu, Juan, et al.
Publicado: (2019)

FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models
por: Jiang, Yumin, et al.
Publicado: (2023)

The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells
por: Fujimaki, Ayaka, et al.
Publicado: (2023)

Ibudilast Attenuates Folic Acid–Induced Acute Kidney Injury by Blocking Pyroptosis Through TLR4-Mediated NF-κB and MAPK Signaling Pathways
por: Li, Xue, et al.
Publicado: (2021)

Resveratrol Attenuates High Glucose-Induced Osteoblast Dysfunction via AKT/GSK3β/FYN-Mediated NRF2 Activation
por: Xuan, Yue, et al.
Publicado: (2022)

Shikonin Attenuates Acetaminophen-Induced Hepatotoxicity by Upregulation of Nrf2 through Akt/GSK3β Signaling
por: Li, Huachao, et al.
Publicado: (2018)

A-Lipoic Acid Alleviates Folic Acid-Induced Renal Damage Through Inhibition of Ferroptosis
por: Li, Xue, et al.
Publicado: (2021)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

The plasma membrane H(+)‐ATPase FgPMA1 regulates the development, pathogenicity, and phenamacril sensitivity of Fusarium graminearum by interacting with FgMyo‐5 and FgBmh2
por: Wu, Luoyu, et al.
Publicado: (2021)

Meta-analysis and systematic review of intravascular ultrasound versus angiography-guided drug eluting stent implantation in left main coronary disease in 4592 patients
por: Wang, Yue, et al.
Publicado: (2018)

Barrier properties of Nup98 FG phases ruled by FG motif identity and inter-FG spacer length
por: Ng, Sheung Chun, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

Puerarin pretreatment attenuates cardiomyocyte apoptosis induced by coronary microembolization in rats by activating the PI3K/Akt/GSK-3β signaling pathway
por: Chen, Zhi-Qing, et al.
Publicado: (2021)

Roxadustat and thyroid-stimulating hormone suppression
por: Tokuyama, Atsuyuki, et al.
Publicado: (2021)

Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy
por: Sun, Dongdong, et al.
Publicado: (2011)

Daidzein ameliorated concanavalin A-induced liver injury through the Akt/GSK-3β/Nrf2 pathway in mice
por: Li, Shang-Lin, et al.
Publicado: (2021)

Ginsenoside Rd Attenuates Myocardial Ischemia/Reperfusion Injury via Akt/GSK-3β Signaling and Inhibition of the Mitochondria-Dependent Apoptotic Pathway
por: Wang, Yang, et al.
Publicado: (2013)

Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis
por: Yan, Pengju, et al.
Publicado: (2023)

Copper Tolerance Mediated by FgAceA and FgCrpA in Fusarium graminearum
por: Liu, Xin, et al.
Publicado: (2020)

eFG: an electronic resource for Fusarium graminearum
por: Liu, Xiaoping, et al.
Publicado: (2013)

F.G. : un bárbaro entre la belleza /
por: Gómez, Flavio
Publicado: (1972)

Gallic Acid Attenuates Platelet Activation and Platelet-Leukocyte Aggregation: Involving Pathways of Akt and GSK3β
por: Chang, Shih-Sheng, et al.
Publicado: (2012)

Sodium Dichloroacetate Stimulates Angiogenesis by Improving Endothelial Precursor Cell Function in an AKT/GSK-3β/Nrf2 Dependent Pathway in Vascular Dementia Rats
por: Zhao, Hui, et al.
Publicado: (2019)

Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS
por: Yu, Jing, et al.
Publicado: (2021)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
por: Yasuoka, Yukiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_id6b1cn40bltga8g678o8o7hjt